Résumé des résultats (Abstract)
(Anglais)
|
Metastatic bone cancer is an incurable disease and one of the most complex cancers to treat. Due to the high dose, tumour imaging is
currently performed at the beginning and end of standard particle radio-therapy (PRT), making personalised treatment difficult. The main
goal of BoneOscopy is to develop a radically new technology to enable informed medical decisions by monitoring bone cancer on a daily
basis during PRT. At the heart of BoneOscopy is the ability to detect prompt gamma (PGs) emitted by cancer during PRT and separate
them from healthy tissue, unlocking the full potential of spectroscopic analysis without the need for additional dose. The development of a
highly specialised detection and collimation system will enable accurate spectroscopic analysis of a very small volume or region within the
cancer. As the number of PRT centres grows, we anticipate that within 10 years BoneOscopy will benefit all patients treated with proton
and carbon ions. The objectives of BoneOscopy will be achieved by its interdisciplinary consortium, which brings together six partners
from five European countries with key expertise in bioengineering and PRT (DKFZ), medical physics and engineering (CSIC), fast
electronics for PRT (LIP), Monte Carlo simulations and clinical PRT experience (THM), turnkey software for high performance medical
devices (Cosylab) and EU project management, communication and dissemination (accelCH). If achieved, the proposed science-totechnology
breakthrough will have a transformative impact on current cancer treatment by providing a safe, personalised and quantitative
measure of daily treatment efficacy, thereby contributing to the global fight against cancer. In summary, BoneOscopy will lead to a
significant reduction in the health burden in Europe and worldwide, improved quality of life for patients, reduced costs for healthcare
systems and improved sustainability of healthcare.
|
